2. UroToday Home
  3. Video Lectures

ESMO 2021 Videos

Cabazitaxel as a Third-Line Treatment After Docetaxel and an Androgen Receptor Targeting Agent in mCRPC Patients – Alicia Morgans
December 27, 2021
Details
Enzalutamide Plus Talazoparib vs Placebo Plus Enzalutamide in Men With DDR Gene Mutations, the TALAPRO-3 Trial in mCSPC – Neeraj Agarwal
November 29, 2021
Details
Practice-Changing and Emerging Treatment Strategies in Metastatic Urothelial Carcinoma - Guru Sonpavde
November 18, 2021
Details
Preliminary Results of MGC018, an anti B7-H3 Antibody Drug Conjugate in mCRPC – Eugene Shenderov
November 18, 2021
Details
Tazemetostat in Combination With Abiraterone + Prednisone or Enzalutamide in mCRPC – Wassim Abida
November 12, 2021
Details
Cabazitaxel in Male Patients with Chemotherapy Pre-Treated Metastatic Germ-Cell Tumors CABA-GCT - Giulia Baciarello
November 10, 2021
Details
Prospective Analysis of The Effect of Germline Mutations on Outcomes for mCRPC Patients Treated With Radium-223 (PRORADIUM) – Elena Castro
November 9, 2021
Details
CheckMate 9KD Trial CohortA2 Evaluating Nivolumab + Rucaparib for Chemotherapy-Naïve mCRPC - Daniel Petrylak
November 7, 2021
Details
Cisplatin-Related Immunomodulation and Efficacy with Atezolizumab + Cisplatin Versus Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer - Matthew Galsky
November 4, 2021
Details
Sabizabulin in Men with Metastatic Castration Resistant Prostate Cancer - Mark Markowski
October 31, 2021
Details
Time Course Profile of Adverse Events With Darolutamide in the ARAMIS Trial – Christian Gratzke
October 27, 2021
Details
Cognitive Assessment in Men with Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Randomly Receiving Darolutamide or Enzalutamide in the ODENZA Trial - Karim Fizazi
October 16, 2021
Details
Darolutamide Maintenance in mCRPC Previously Treated with Novel Hormonal Agents - Richard Cathomas
October 16, 2021
Details
Therapy Resistance Identified in Circulating Tumor Cell Morphologic Sub-Types Present Prior to Treatment in the CARD Trial - Cora Sternberg
October 15, 2021
Details
Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer – Ravi Madan
October 15, 2021
Details
PSMAfore Trial - Evaluating 177Lu-PSMA-617 in Chemotherapy-Naïve mCRPC Patients – Michael Morris
October 15, 2021
Details
COSMIC-021 Study: A Breakthrough in Metastatic CRPC Treatment with Cabozantinib and Atezolizumab - Neeraj Agarwal
October 4, 2021
Details
First-in-Human Study of FOR46 in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC) – Rahul Aggarwal
October 3, 2021
Details
Pain and Symptomatic Skeletal Events Reported in the VISION Trial – Oliver Sartor
October 3, 2021
Details
Frontline Cabozantinib in Metastatic Collecting Ducts Renal Cell Carcinoma – Giuseppe Procopio
September 28, 2021
Details
Evaluating the Efficacy of Sabizabulin in The Treatment of Metastatic Castration-Resistant Prostate Cancer – Robert Dreicer
September 28, 2021
Details
STAMPEDE Analysis of Abiraterone With or Without Enzalutamide Added to Androgen Deprivation Therapy Compared to ADT Alone In High-Risk Non-Metastatic Prostate Cancer Patients– Gerhardt Attard
September 20, 2021
Details
Final Results of Phase I/II Trial of Fractionated Dose 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Scott Tagawa
September 20, 2021
Details
Combined Testosterone Therapy with Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer – Michael Schweizer
September 20, 2021
Details
Relugolix in the Phase 3 HERO Study in Men with mHSPC - Bertrand Tombal
September 19, 2021
Details
Overall Survival Results of PEACE-1 a Phase 3 Trial in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Karim Fizazi
September 19, 2021
Details
Health-Related Quality of Life (HRQoL) From the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer – Karim Fizazi
September 19, 2021
Details
Radiopharmaceuticals in Prostate Cancer: A Deep Dive into Patient-Reported Outcomes - Scott Tagawa
September 15, 2021
Details
PSMAddition, the Integration of Lutetium-177 With the Standard of Care Therapy in Metastatic Castrate-Sensitive Prostate Cancer Patients – Scott Tagawa & Oliver Sartor
June 18, 2021
Details